Antibody-dependent enhancement (ADE) or “immune enhancement” of viral entry has been observed for many viruses and is a major concern for vaccine development and antibody-based drug therapies. ADE occurs when antibodies from a previous infection or vaccination facilitate viral entry into host cells and enhance viral infection in these cells.
University of Pittsburgh School of Medicine scientists have isolated the smallest biological molecule to date that completely and specifically neutralizes the SARS-CoV-2 virus, which is the cause of COVID-19. This antibody component, which is 10 times smaller than a full-sized antibody, has been used to construct a drug–known as Ab8–for
Immunoglobulins (Ig) or antibodies serve as key detection molecules in the immune system. Antibodies refers to proteins that are produced in B-lymphocytes by the body’s immune system in response to foreign substances or infections, including bacteria or viruses. There are five major classes (isotypes) of immunoglobulins: IgA (immunoglobin A) IgD